Zusanli (ST36) Acupoint Injection with Neostigmine for Paralytic Postoperative
Ileus following Radical Gastrectomy for Gastric Cancer: a Randomized Clinical
Trial
#MMPMID30026821
You X
; Wang Y
; Wu J
; Liu Q
; Liu Y
; Qian Y
; Chen J
; Tang D
; Wang D
J Cancer
2018[]; 9
(13
): 2266-2274
PMID30026821
show ga
Background: The Zusanli (ST36) acupoint has been associated with treatment of
various gastrointestinal conditions. There have been no studies of acupuncture
therapy for paralytic postoperative ileus (PPOI). Materials and methods: Patients
with PPOI following gastrectomy for gastric cancer were randomized to receive
ST36 acupoint injection with neostigmine, gluteal intramuscular injection with
1.0 mg neostigmine, ST36 acupuncture alone, or standard therapy. The main outcome
was the effectiveness rate for recovery of peristalsis. Secondary outcomes were
time to bowel sound recovery, time to first flatus, and time to first defecation.
Tertiary outcomes were drug-related adverse events, including abdominal pain,
diarrhea, nausea, vomiting, tearing, delirium, seizure, and anxiety. Results:
ST36 acupoint injection with neostigmine and gluteal intramuscular injection of
neostigmine gave a higher rate of peristalsis recovery, and the ST36 acupoint
injection group showed significantly higher total effectiveness rate than that of
the intramuscular injection group. These interventions gave significantly shorter
times to bowel sound recovery, shorter times to first flatus and first defecation
compared with ST36 acupuncture and standard post-operative therapy (P < 0.01).
ST36 acupoint injection group gave shorter time to bowel sound recovery, shorter
time to first flatus and first defecation than those of the intramuscular
injection group (P < 0.01). Drug-related adverse events in the intramuscular
injection group were more serious than in the ST36 acupoint injection group (P <
0.05). Conclusion: ST36 acupoint injection with neostigmine is safe and effective
for treatment of PPOI.
free
free
free
